Inclusion of pregnant women in COVID-19 clinical trials would allow evaluation of effective
therapies that might improve maternal health, pregnancy, and birth outcomes, and avoid the …

The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health problem. The …

SARS-CoV-2 has ushered a global pandemic with no effective drug being available at
present. Although several FDA-approved drugs are currently under clinical trials for drug …

Background There is little evidence about how novel coronavirus (SARS-CoV-2) affects
pregnant women and their newborns. Comparisons with other members of the coronavirus …

From the beginning of the Coronavirus Disease 2019 (COVID-19) pandemic, special
attention has been paid to pregnant women and to monitoring comorbidities, such as …

The main protease (Mpro) of SARS-CoV-2 has been recognized as an attractive drug target
because of its central role in viral replication. Our previous preliminary molecular docking …

Constant accumulation of data results in continuous updates of guidelines and
recommendations on the proper management of pregnant women with COVID-19. This …

The global pandemic of COVID-19 is currently ongoing. Clinical evidence shows that
specific population groups such as the elderly, individuals with comorbidities, and pregnant …

This retrospective cohort study aimed to analyze the clinical manifestations, complications,
and maternal-fetal outcomes in patients affected by severe acute respiratory syndrome …

Evidence indicates that SARS-CoV-2 infection increases the likelihood of adverse
pregnancy outcomes. Modifications in the circulatory, pulmonary, hormonal, and …